SPAC for 2025 BLA: Non-viral gene therapy biotech enGene, steered by ex-Mythic leaders, finds Forbion blank check
Nearing a Phase II for its non-viral gene therapy, a small Canadian biotech plans to combine with a Forbion-led blank check …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
